Industry News
Excerpt from the Article: Using automated machine learning to calculate the right ventricle/left ventricle (RV/LV) ratio can help radiologists identify patients who have pulmonary hypertension (PH) and would benefit from being referred to a specialist. In a presentation during the 2021 European Congress of Radiology annual meeting, Pia Charters from Royal United Hospital Bath NHS…
Read More
Excerpt from the Article: As the COVID-19 pandemic enters its second year, scientists are still working to understand how the SARS-CoV-2 strain evolved, and how it became so much more dangerous than other coronaviruses, which humans have been living alongside for millennia. Virologists and epidemiologists worldwide have speculated for months that a protein called ORF8…
Read More
Excerpt from the Press Release: EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its discovery engine has isolated potent antibodies capable of neutralizing several SARS-CoV-2 variants, including the South African Variant (B.1.351), in pseudovirus testing. This…
Read More
Excerpt from the Press Release: LEXINGTON, Mass., Feb. 18, 2021 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces publication of two pivotal studies that provided the basis for approval of Leukine (sargramostim, yeast-derived rhu GM-CSF) to improve survival in patients exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome…
Read More
Excerpt from the Press Release: OXFORDSHIRE, England and CONSHOHOCKEN, Pa. and ROCKVILLE, Md., Feb. 19, 2021 (GLOBE NEWSWIRE) — Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today…
Read More
Excerpt from the Article: MRI scans reveal myocarditis, scarring, infarction, and ischemia in recovered patients with elevated troponin levels. Roughly 50 percent of patients who recover after being hospitalized with severe COVID-19 suffer heart damage. MRI scans, conducted at least one month post-discharge, show patients who have elevated levels of troponin show evidence of heart…
Read More
Excerpt from the Press Release: Neutralizing antibodies develop within two weeks of a SARS-CoV-2 infection, but their durability and intensity can vary by individual, prompting concerns about the prospects of long-lasting immunity and efficacy of COVID-19 vaccines. In a PLOS ONE paper, published online February 11, 2021, researchers at University of California San Diego School…
Read More
Excerpt from the Article: CT, MRI, and ultrasound images reveal the myriad of ways the virus prompts the body to attack itself – with this knowledge, radiologists can better contribute to treatment planning. Not only does COVID-19 attack the body, but radiology images show that the virus can actually make the body attack itself. For…
Read More
Excerpt from the Press Release: Scientists at Sanford Burnham Prebys Medical Discovery Institute have designed a next-generation drug, called SBP-7455, which holds promise as a treatment for triple-negative breast cancer—an aggressive cancer with limited treatment options. The drug blocks a cellular recycling process called autophagy, which cancer cells hijack as a way to resist treatment.…
Read More
Excerpt from the Press Release: BOSTON, Feb. 08, 2021 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced the publication of new data highlighting the highly potent in vitro antiviral activity of AT-527 against SARS-CoV-2. AT-527 is an orally administered, direct-acting antiviral developmental agent derived from Atea’s purine nucleotide…
Read More